Skip to Content
Merck
CN

P4484

Purvalanol A

≥98% (HPLC), powder

Synonym(s):

2-(1R-Isopropyl-2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine, NG-60

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C19H25ClN6O
CAS Number:
Molecular Weight:
388.89
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)/t15-/m0/s1

SMILES string

CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c3ncn(C(C)C)c3n1

InChI key

PMXCMJLOPOFPBT-HNNXBMFYSA-N

assay

≥98% (HPLC)

form

powder

solubility

methylene chloride: 50 mg/mL

shipped in

dry ice

storage temp.

−20°C

Biochem/physiol Actions

Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor.
Purvalanol A is found to inhibit ABCG2 (ATP-binding cassette G2) transporter in vitro. It is also known to attenuate cellular Src kinase action and induce cell cycle arrest at the G2 to M phase transition.

Features and Benefits

This compound is featured on the CDKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cancer: New Insights for the Healthcare Professional, 927-927 (2012)
Katarina Bacevic et al.
Nature communications, 8(1), 1995-1995 (2017-12-10)
Adaptive therapy (AT) aims to control tumour burden by maintaining therapy-sensitive cells to exploit their competition with resistant cells. This relies on the assumption that resistant cells have impaired cellular fitness. Here, using a model of resistance to a pharmacological
Andrey Kan et al.
PloS one, 11(1), e0146227-e0146227 (2016-01-08)
Adaptive immune responses are complex dynamic processes whereby B and T cells undergo division and differentiation triggered by pathogenic stimuli. Deregulation of the response can lead to severe consequences for the host organism ranging from immune deficiencies to autoimmunity. Tracking
Ling Yin et al.
Cell death & disease, 10(6), 385-385 (2019-05-18)
SE translocation (SET), an inhibitor of protein phosphatase 2A (PP2A), plays important roles in mitosis and possesses oncogenic activity in several types of cancer. However, little is known regarding its regulation. Here we reveal a novel phosphorylation site of SET
Anthraquinones?Advances in Research and Application: 2012 Edition, 4-4 (2012)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service